Biotron Ltd. (OTC: BITRF) is an Australian biotechnology company based in Sydney. The company develops and commercializes novel small molecule antiviral therapeutics targeting Hepatitis C virus (HCV) and HIV-1. Biotron’s lead drug, BIT225 is in clinical development for treatment of … Continue reading →

Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV) is a biopharmaceutical company focused on the development of therapeutic candidates for the simultaneous treatment of various clinical conditions. Kitov focuses on developing combinations of existing drugs in advanced stages of development. Kitov’s lead … Continue reading →

Rexahn Pharmaceuticals, Inc. (NYSE: RNN) is a clinical-stage biopharmaceutical company dedicated to the development of novel, best-in-class therapeutics for the treatment of cancer. The company’s product candidates work by targeting and neutralizing specific proteins believed to be involved in the … Continue reading →

BIND Therapeutics, Inc. (NASDAQ: BIND) is a clinical-stage nanomedicine company developing a pipeline of ACCURINS®, its novel targeted therapeutics designed to increase the concentration and duration of therapeutic payloads at disease sites while reducing exposure to healthy tissue. The company … Continue reading →

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is focused on discovering, developing and marketing first-in-class therapeutics for the treatment of diseases. Presently, the company is positioned at the forefront of one of the largest segments of the U.S. healthcare industry:  heart disease. … Continue reading →

Neurometrix (NASDAQ: NURO) is an innovative health-care company that develops wearable medical technology and point-of-care test that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. The company’s expertise in biomedical engineering has been refined over … Continue reading →

InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) is on a quest to redefine the life of the spinal cord injury patient. Armed with cutting-edge technology and MIT science, experienced business and medical professionals at InVivo Therapeutics are pushing the boundaries of … Continue reading →

Fate Therapeutics, Inc. (NASDAQ: FATE) is a clinical‑stage biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life‑threatening diseases. The company is primarily focused on developing programmed hematopoietic cellular candidates as therapeutic entities for … Continue reading →

CymBay Therapeutics, Inc. (NASDAQ: CBAY) is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. The company’s portfolio includes arhalofenate, which has shown two therapeutic actions in a … Continue reading →

Pulmatrix, Inc. (NASDAQ: PULM) is developing innovative inhaled therapies to address serious pulmonary disease using its clinically validated, proprietary iSPERSE technology. Leveraging the unique capabilities of iSPERSE to dramatically advance inhalation technology, the company means to create new therapies to … Continue reading →